Author

Sasikumar Kotagiri

The University of Texas MD Anderson Cancer CenterPrimary ORCID profile (0000-0002-7185-1289 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Sasikumar KotagiriiD1 paper · The University of Texas MD Anderson Cancer Center

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Hira MazhariD· 1 shared Manu M. SebastianiD· 1 shared Nicholas BlazaniniD· 1 shared Phuong Kieu Nguyen· 1 shared Xiaobing Liang· 1 shared Yanyan HaniD· 1 shared Yawen WangiD· 1 shared Yonathan LissanuiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Hira MazharORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors.

Sasikumar Kotagiri, Yawen Wang, Yanyan Han, Xiaobing Liang, Nicholas Blazanin, Hira Mazhar, Manu M. Sebastian, Phuong Kieu Nguyen, Yongying Jiang, Yonathan Lissanu

This paper discovers and characterizes potent SMARCA2 PROTACs that show anti-tumor activity and synergize with KRAS G12C inhibitors in SMARCA4 mutant lung cancer.

Journal of Medicinal Chemistry · Apr 25, 2025Peer-reviewedCancer Biology